PDCD1 and cancer: The negative correlation between PD1 signaling and the prognostic factors indicates that targeting the PD1 immune checkpoint during cancer immunotherapy may contribute to atherosclerosis development and ischemic risk through the macrophage related ceRNA subnetwork.